What one share of Immix Biopharma holds
Immix Biopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.84 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.82 |
| Cash and investments | $3.15 |
| Book value | $3.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$0.34 | — | — | — | −$1.40 |
| 2021 | — | −$6.64 | $0.00 | −$0.43 | — | — |
| 2022 | — | −$0.59 | — | — | — | $0.95 |
| 2023 | — | −$0.89 | $0.00 | −$0.66 | — | $0.82 |
| 2024 | — | −$0.76 | $0.04 | −$0.56 | — | $0.48 |
| 2025 | — | −$0.89 | $0.02 | −$0.75 | — | $1.77 |
Common questions about Immix Biopharma
How much does one share of Immix Biopharma earn?
Over the last 12 months, Immix Biopharma lost $0.84 for each share.
Does Immix Biopharma pay a dividend?
Immix Biopharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Immix Biopharma’s book value per share?
Immix Biopharma’s book value is $3.20 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Immix Biopharma have?
Each share of Immix Biopharma has $3.15 of cash and investments, as of June 30, 2026.
What is Immix Biopharma’s free cash flow per share?
−$0.82 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Immix Biopharma bought back shares?
Immix Biopharma’s share count rose about 877% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.